Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes : Episode 8
Comparison of Safety Profiles of EGFR Inhibitors
Key opinion leaders compare osimertinib's adverse event profile to other EGFR inhibitors, highlighting specific challenges and benefits observed in clinical practice
Video content above is prompted by the following:
- In your experience, how does osimertinib’s adverse event profile compare to other EGFR inhibitors?
- Are there specific challenges or benefits you’ve observed with osimertinib?
Recent Videos
Related Content
